LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Aktien・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

719.66 -0.26

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

708.04

Max

729.83

Schlüsselkennzahlen
By Trading Economics
Einkommen	-117M 727M
Verkäufe	-279M 3.6B
KGV Branchendurchschnitt	17.122 49.8
EPS	9.47
Dividendenrendite	0.51
Gewinnspanne	20.17
Angestellte	15,343
EBITDA	-234M 967M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+22.32% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	0.51% 2.25%
Nächstes Ergebnis	31. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-3.7B 74B
Vorheriger Eröffnungskurs	719.92
Vorheriger Schlusskurs	719.66

Nachrichtenstimmung

By Acuity

37%

63%

103 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

542.44 / 599.76 Unterstützung & Widerstand

Regeneron Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Regeneron Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

22.32% Vorteil

12-Monats-Prognose

Durchschnitt 884.89 USD 22.32%

Hoch 1,057 USD

Tief 762 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Regeneron Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

Buy

Halten

Sell

Basierend auf 19 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Regeneron Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

542.44 / 599.76Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

103 / 346 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.